The content on this site is intended for healthcare professionals only
Dr Silvia Marsoni, Director of clinical research at The Institute for Cancer Research in Candiolo, talks to ecancer about primary and secondary resistance in colorectal cancer at the European Forum on Oncology in Berlin, May 2012.
Dr Marsoni’s project aims to understand how patients respond to EGF therapy and why the majority do not respond to treatment. In order to take this back to the lab, mouse models are used to mimic the immune system of the patient. The data can then be used, again, in the clinic to improve and treatment.
Social determinants and survival outcomes in early-onset colorectal cancer in the US
Made to measure: Choosing the optimal regimen in transplant-eligible NDMM
Advancements in paediatric Acute lymphoblastic leukemia management
ESMO 2024: Optimising the personalisation of prostate cancer treatment
Multiple myeloma In Rwanda: The need for further research
Addressing the rise of multiple myeloma in Rwanda
GIST tumours and soft tissue sarcomas
Best practice in HRRm testing in patients with metastatic prostate cancer
Relapsed refractory multiple myeloma
